4.8 Article

MLL4 Is Required to Maintain Broad H3K4me3 Peaks and Super-Enhancers at Tumor Suppressor Genes

期刊

MOLECULAR CELL
卷 70, 期 5, 页码 825-+

出版社

CELL PRESS
DOI: 10.1016/j.molcel.2018.04.028

关键词

-

资金

  1. NIH/NCI at the University of Texas MD Anderson Cancer Center [P30CA16672]
  2. IDDRC neuropathology core [U54HD083092]
  3. Cancer Prevention and Research Institute of Texas (CPRIT) [RP140271]
  4. NIH [R01CA157919, R01CA207098, R01CA207109, R35CA197569, R01HG007538, R01CA193466, R01NS079715, R03NS077021, R01NS089664, R35CA197452, R01HL133254]
  5. Center for Cancer Epigenetics at the MD Anderson Cancer Center
  6. CPRIT [RP150292, RP150301]
  7. startup funds from the Methodist Hospital Research Institute

向作者/读者索取更多资源

Super-enhancers are large clusters of enhancers that activate gene expression. Broad trimethyl histone H3 lysine 4 (H3K4me3) often defines active tumor suppressor genes. However, how these epigenomic signatures are regulated for tumor suppression is little understood. Here we show that brain-specific knockout of the H3K4 methyltransferase MLL4 (a COMPASS-like enzyme, also known as KMT2D) in mice spontaneously induces medulloblastoma. Mll4 loss upregulates oncogenic Ras and Notch pathways while downregulating neuronal gene expression programs. MLL4 enhances DNMT3A-catalyzed DNA methylation and SIRT1/BCL6-mediated H4K16 deacetylation, which antagonize expression of Ras activators and Notch pathway components, respectively. Notably, Mll4 loss downregulates tumor suppressor genes (e.g., Dnmt3a and Bcl6) by diminishing broad H3K4me3 and super-enhancers and also causes widespread impairment of these epigenomic signatures during medulloblastoma genesis. These findings suggest an anti-tumor role for super-enhancers and provide a unique tumor-suppressive mechanism in which MLL4 is necessary to maintain broad H3K4me3 and super-enhancers at tumor suppressor genes.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据